Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Pityriasis Rubra Pilaris Clinical Trial

Official title: Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Dermatitis, Exfoliative
• Pityriasis Rubra Pilaris

• NCT number: NCT06444399
• Study type: Interventional
• Source: Mayo Clinic
• Contact: Aaron Mangold, MD
• Phone: (480) 301-8000
• Email: mangold.aaron@mayo.edu
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 1, 2024
• Completion date: July 1, 2025